Skip to content

Clinical trials

HIV Infections trials in Brazil

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: HIV Infections Country / region: Brazil Clear all

140 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20015
20022
20035
20049
20057
200610
20079
20087
200910
20107
20114
20124
20134
20142
20155
20163
20175
20182
20194
20202
20216
20224
20234
20242
20252
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed112
Recruiting9
Terminated7
Unknown status6
Active, not recruiting3
Not yet recruiting2
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)37
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections12
ViiV Healthcare11
Oswaldo Cruz Foundation8
Boehringer Ingelheim7
Bristol-Myers Squibb6
Tibotec Pharmaceuticals, Ireland5
Abbott4
Gilead Sciences3
Hospital de Clinicas de Porto Alegre3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
HIV Infections140
Acquired Immunodeficiency Syndrome22
Tuberculosis11
Hepatitis B4
Infections4
Sexually Transmitted Diseases3
Coinfection2
Disease Progression2
Dyslipidemias2
HIV Seropositivity2

Trials

Showing 1 to 25 of 140. Each trial links to its page on Pharma Observatory.

40 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.